News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,019 Results
Type
Article (13491)
Company Profile (103)
Press Release (245425)
Section
Business (87835)
Career Advice (460)
Deals (15317)
Drug Delivery (60)
Drug Development (36472)
Employer Resources (49)
FDA (6235)
Job Trends (6179)
News (149762)
Policy (13994)
Tag
Academia (435)
Africa (312)
Alliances (23045)
Alzheimer's disease (325)
Approvals (6215)
Arizona (35)
Artificial intelligence (40)
Asia (19640)
Australia (2533)
Bankruptcy (143)
Best Places to Work (4208)
Biosimilars (31)
Biotechnology (44)
C2C Services and Suppliers (10597)
California (610)
Canada (440)
Cancer (154)
Career advice (402)
Cell therapy (23)
China (68)
Clinical research (30061)
Collaboration (55)
Compensation (26)
Connecticut (25)
COVID-19 (738)
Cystic fibrosis (22)
Data (107)
Diabetes (27)
Diagnostics (1202)
Drug pricing (48)
Earnings (31140)
Employer resources (43)
Europe (38409)
Events (36278)
Executive appointments (86)
FDA (6305)
Florida (76)
Funding (39)
Gene therapy (41)
GLP-1 (262)
Government (1250)
Healthcare (3508)
Hotbed/Location (177913)
Illinois (70)
Indiana (59)
Infectious disease (742)
Inflammatory bowel disease (41)
Interviews (57)
IPO (5782)
Job creations (2046)
Job search strategy (371)
Kansas (49)
Layoffs (164)
Legal (3398)
Lung cancer (33)
Manufacturing (45)
Maryland (92)
Massachusetts (533)
Medical device (1251)
Medtech (1253)
Mergers & acquisitions (9479)
Metabolic disorders (103)
Minnesota (37)
Neuroscience (379)
New Jersey (255)
New York (170)
NextGen Class of 2024 (1576)
Non-profit (588)
North Carolina (226)
Northern California (268)
Obesity (63)
Ohio (29)
Opinion (106)
Patents (40)
Pennsylvania (187)
People (28243)
Pharmaceutical (59)
Phase I (7822)
Phase II (12708)
Phase III (11417)
Pipeline (49)
Podcasts (36)
Policy (37)
Postmarket research (1398)
Preclinical (3132)
Press Release (25)
Rare diseases (52)
Real estate (2624)
Regulatory (9692)
Research institute (561)
Resumes & cover letters (55)
South America (497)
Southern California (272)
Startups (1623)
Texas (82)
United States (2695)
Vaccines (92)
Virginia (22)
Washington State (48)
Weight loss (55)
Date
Today (44)
Last 7 days (211)
Last 30 days (812)
Last 365 days (13308)
2024 (9371)
2023 (14244)
2022 (19556)
2021 (20070)
2020 (19034)
2019 (14888)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
259,019 Results for "phio pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio’s Patented INTASYL Compound
Phio’s INTASYL compound targets aging skin disorders
August 6, 2024
·
3 min read
Policy
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Phio’s Compound RXI-185 is designed to slow progression of UV induced collagen breakdown
June 18, 2024
·
4 min read
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells
May 24, 2024
·
3 min read
Genetown
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that a Safety Monitoring Committee (SMC) reviewed safety data from the first dose cohort treated in the Phase 1b clinical trial with Phio’s lead compound PH-762.
May 28, 2024
·
3 min read
Press Releases
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
September 16, 2024
·
3 min read
Press Releases
Phio Pharmaceuticals Announces New Chief Financial Officer
August 1, 2024
·
1 min read
Press Releases
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 9, 2024
·
3 min read
Press Releases
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT
August 29, 2024
·
3 min read
Genetown
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
April 11, 2024
·
3 min read
Phio Pharmaceuticals Announces Reverse Stock Split
July 2, 2024
·
4 min read
1 of 25,902
Next
